
Cognition Therapeutics fell 54.8% from $1.33 to $0.60, behind the S&P 500's +9.7%. Its worst day was Jun 24 (−38.2%), and its low came Mar 30 at $0.59.
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Cognition Therapeutics closed at its highest level of the year, 35.3% above where the year started.
+3.4% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
EPS of $-0.01 beat the $-0.07 estimate on $0.00 revenue.
−2.7% · S&P 500 −1.8%
EPS of $-0.05 beat the $-0.07 estimate on $0.00 revenue (est. $880,000.00).
+4.3% · S&P 500 +0.8%
Cognition Therapeutics shares rose 16.2%, while the S&P 500 rose 1.0%.
+16.2% · S&P 500 +1.0%
Cognition Therapeutics, Inc., (the "Company" or "Cognition") (NASDAQ:CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, today announced that it received
−38.2%, the year's worst day, on 12M shares, the year's heaviest volume · S&P 500 0.0%
EPS of $-0.04 beat the $-0.06 estimate on $0.00 revenue (est. $1.0M).
−4.4% · S&P 500 +0.6%
EPS of $-0.04 beat the $-0.07 estimate on $0.00 revenue (est. $1.1M).
−7.0% · S&P 500 −4.4%
Where it ended: a close of $0.60 on Nov 19, 2026.
Nothing in the past 12 months.
All CGTX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CGTX and SPY from Benzinga historical bars. Not investment advice.